A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers
Abstract
Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that may develop de novo or as a mechanism of treatment resistance. N-myc is capable of driving NEPC progression. Alisertib inhibits the interaction between N-myc and its stabilizing factor Aurora-A, inhibiting N-myc signaling, and suppressing tumor growth.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2019
- Source ID
- 10.1158/1078-0432.ccr-18-1912
Entities
People
- Alessandro Romanel
- Andrea Sboner
- Andrew J. Armstrong
- Bruce Montgomery
- Christopher Hoimes
- Clara Oromendia
- Daniel C. Danila
- David M. Nanus
- David S. Rickman
- Davide Prandi
- Etienne Dardenne
- Francesca Demichelis
- Himisha Beltran
- Howard I. Scher
- Jacek Pinski
- Juan M. Mosquera
- Karla V. Ballman
- Loredana Puca
- Mark Rubin
- Mark Stein
- Naveen Gumpeni
- Rohan Bareja
- Russell Z. Szmulewitz
- Scott T Tagawa
- Ulka Vaishampayan
- Verena Sailer
Organizations
- Case Western Reserve University
- Duke University
- Memorial Sloan Kettering Cancer Center
- National Institutes of Health
- Rutgers University
- United States Department of Defense
- University of Chicago
- University of Southern California
- University of Trento
- University of Washington
- Wayne State University
- Weill Cornell Medicine